THE WOODLANDS, Texas,
June 24, 2013 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company
focused on discovering breakthrough treatments for human disease,
delivered two oral and two poster presentations on LX4211 at the
73rd Scientific Sessions of the American Diabetes
Association (ADA) in Chicago, on
June 23, 2013.
Pablo Lapuerta, M.D., Lexicon's
executive vice president, clinical development and chief medical
officer, delivered an oral presentation titled "LX4211, a Dual
Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, Reduces
Blood Pressure in Patients with Type 2 Diabetes." This
presentation highlighted the reductions in blood pressure by LX4211
for subgroups with varying blood pressures at baseline in a 12-week
dose-ranging Phase 2b study of 299 patients with type 2 diabetes.
Patients with high baseline systolic blood pressure (>130 mmHg)
dosed with LX4211 experienced an average of 14 mmHg reduction in
systolic blood pressure when compared to placebo (p=0.002). In
contrast, patients with normal systolic blood pressure at baseline
(<130 mmHg) experienced an average of 1 mmHg reduction (p=0.6).
Systolic blood pressure readings below 100 mmHg, as well as
orthostatic systolic blood pressure changes (changes due to a shift
in position such as seated-to-standing and supine-to-standing),
were no different between patients treated with LX4211 and those on
placebo.
"This new analysis of data from the trial shows that LX4211
lowers blood pressure to a greater extent in those patients who are
in the greatest need of treatment, that is, those patients with
hypertension," said Dr. Lapuerta. "Furthermore, patients with
normal blood pressure showed little or no change on LX4211
treatment, a promising finding in regard to future development of
LX4211."
Brian Zambrowicz, Ph.D.,
Lexicon's executive vice president and chief scientific officer,
delivered an oral presentation titled "LX4211, a Dual
SGLT1/SGLT2 Inhibitor, Decreases Body Weight and Triglycerides in
Patients with Type 2 Diabetes Mellitus and Elevated Baseline
Values." This presentation highlighted the reductions in
body weight and triglycerides by LX4211 for subgroups with varying
body mass indexes (BMI) and triglyceride levels at baseline in the
same Phase 2b study. Patients with baseline BMI>30 treated
with 200 mg once-daily, 200 mg twice-daily and 400 mg once-daily
treatment all experienced greater average body weight reductions
than placebo (p<0.001). Patients with high baseline
triglycerides, between 200 and 500 mg/dL, experienced reductions
with LX4211 treatment that were significantly larger than those
experienced by patients with baseline triglycerides lower than 200
mg/dL in three of the four LX4211 doses tested.
All presentations will be available for download from Lexicon's
corporate website www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has multiple programs in clinical development for diabetes,
irritable bowel syndrome, carcinoid syndrome and other indications,
all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's clinical development
of LX4211, characterizations of the results of and projected timing
of clinical trials of LX4211, and the potential therapeutic and
commercial potential of LX4211. This press release
also contains forward-looking statements relating to Lexicon's
growth and future operating results, discovery and development of
products, strategic alliances and intellectual property, as well as
other matters that are not historical facts or information.
All forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to successfully conduct clinical development of
LX4211 and preclinical and clinical development of its other
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Unless specifically indicated otherwise, results reported as trends
were not statistically significant. Information identifying such
important factors is contained under "Risk Factors" in Lexicon's
annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities
and Exchange Commission. Lexicon undertakes no obligation to
update or revise any such forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.